<div id="readability-page-1"><p>MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) was the target of a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 2,307,824 shares,  a drop of 40.0% from the December 31st total of 3,843,943 shares. Approximately 5.1% of the company's stock are short sold. Based on an average daily volume of 800,131 shares, the short-interest ratio is currently 2.9 days. Based on an average daily volume of 800,131 shares, the short-interest ratio is currently 2.9 days. Approximately 5.1% of the company's stock are short sold.</p><div><p><span></span><span>Get <strong>MBX Biosciences</strong> alerts:</span></p></div><h2>Wall Street Analyst Weigh In</h2><p>MBX has been the subject of several analyst reports. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of MBX Biosciences in a report on Thursday, January 22nd. Stifel Nicolaus boosted their price target on MBX Biosciences from $45.00 to $50.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, December 19th. The Goldman Sachs Group initiated coverage on MBX Biosciences in a report on Thursday, December 4th. They set a &#34;sell&#34; rating and a $18.00 target price for the company. TD Cowen began coverage on shares of MBX Biosciences in a research report on Tuesday, November 4th. They set a &#34;buy&#34; rating for the company. Finally, Guggenheim increased their price objective on shares of MBX Biosciences from $77.00 to $88.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, January 16th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock  has an average rating of &#34;Moderate Buy&#34; and an average price target of $50.20.</p><p><b>Read Our Latest Report on MBX Biosciences</b></p><h2>Institutional Inflows and Outflows</h2><p>Several large investors have recently bought and sold shares of the business. TD Asset Management Inc boosted its position in shares of  MBX Biosciences by 13.1% during the 2nd quarter. TD Asset Management Inc now owns 171,304 shares of the company's stock worth $1,955,000 after purchasing an additional 19,800 shares in the last quarter.  Koa Wealth Management LLC grew its position in  MBX Biosciences by 63.7% during the second quarter. Koa Wealth Management LLC now owns 31,752 shares of the company's stock worth $362,000 after buying an additional 12,356 shares during the period.  Geode Capital Management LLC increased its holdings in  MBX Biosciences by 27.0% in the second quarter. Geode Capital Management LLC now owns 348,447 shares of the company's stock valued at $3,976,000 after buying an additional 73,989 shares in the last quarter.  Intech Investment Management LLC boosted its stake in shares of  MBX Biosciences by 33.0% during the 2nd quarter. Intech Investment Management LLC now owns 14,271 shares of the company's stock worth $163,000 after acquiring an additional 3,543 shares in the last quarter.  Finally, Rockefeller Capital Management L.P. acquired a new stake in shares of  MBX Biosciences in the 2nd quarter worth approximately $389,000. </p><h2>MBX Biosciences Stock Performance</h2><p>MBX stock opened at $36.62 on Friday. The stock has a market cap of $1.64 billion, a P/E ratio of -15.32 and a beta of 0.86. MBX Biosciences has a 12 month low of $4.81 and a 12 month high of $44.89. The firm has a fifty day simple moving average of $33.26. </p><p>MBX Biosciences (NASDAQ:MBX - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.10. </p><h2>MBX Biosciences Company Profile</h2> (Get Free Report)<p>We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.</p><h2>See Also</h2><ul><li>Five stocks we like better than MBX Biosciences</li><li>America’s #1 Chaos Trader: “I’m so #&amp;!$ bullish”</li><li>Trump's NEW Executive Order - BIG Changes Coming to Retirement Accounts</li><li>New Banking Law #1582 Could Unlock $21 Trillion for Americans</li><li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in MBX Biosciences Right Now?</h2><p>Before you consider MBX Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.</p><p>While MBX Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IBBQ

ARKG

SBIO

<p>MBX Biosciences, Inc. (NASDAQ:MBX) experienced a significant decline in short interest, dropping 40% to 2,307,824 shares as of January 15th. Currently, 5.1% of the stock is short sold, with a days-to-cover ratio of 2.9 days. Analysts have mixed ratings, with Weiss Ratings giving a "sell (d-)" and Stifel Nicolaus raising the price target to $50.00. The stock opened at $36.62, with a market cap of $1.64 billion and a P/E ratio of -15.32. The company focuses on developing precision peptide therapies for endocrine and metabolic disorders.</p>

MBX Biosciences, Inc. (NASDAQ:MBX) Short Interest Update